Bio-Techne (TECH) fundamentals: P/E, valuation, undervalued?
Bio-Techne · Health Care · ref. ETF XLV · price $72.47
In short — Bio-Techne trades at 62.5× earnings (P/E), 31.3× forward, with a net margin of 15.0 % and revenue growth of +1 %. Read: Very high P/E (P/E 62 (well above average)).
Is Bio-Techne stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$72.47+33.4% over range
Aug 28, 25low $43.3 · high $72.48Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
0% recommend buying · 10 analysts
Valuation : Very high P/E — P/E 62 (well above average)
Valuation
62.5
P/E (price/earnings)
31.3
Forward P/E
—
PEG
5.4
Price/book (P/B)
$11.4B
Market cap
1.16
EPS
Profitability & growth
15.0 %
Net margin
+1 %
Revenue growth
—
Earnings growth
$289M
Total debt
Bio-Techne income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $1.1B | $285M | 25.1 % |
| 2024 | $1.2B | $168M | 14.5 % |
| 2025 | $1.2B | $73M | 6.0 % |
| 2026 | $1.2B | $182M | 15.0 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Bio-Techne's P/E and is the stock undervalued? What's a good P/E?
Bio-Techne's P/E is 62.5 (forward 31.3). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Very high P/E".
Is Bio-Techne profitable?
Bio-Techne has a net margin of 15.0 % (EPS 1.16). The company is profitable.
Is TECH stock expensive?
Our read: "Very high P/E" — P/E 62 (well above average). Cross-check with growth and sector.
💬 A question about Bio-Techne? The JPI assistant answers using our backtest data.
Keep exploring Bio-Techne